Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

PhaseKin Kinase Regulation by Phase Separation

Coordinator
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV, Germany
Runs
1 September 2024 to 31 August 2029
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101141570

What the project is doing

In the project's own words, from its summary on CORDIS.

Protein phosphorylation is a process that activates biological and cellular pathways. This process is carried out by enzymes called protein kinases that add phosphates to proteins. Protein kinases are crucial drug targets involved in the onset and progression of human diseases such as cancer and Alzheimers disease. Growing evidence suggests that protein kinases are regulated spatially and temporally by the phase separation and condensation of biomolecules into cellular organelles that are not surrounded by membranes.

The molecular mechanisms that govern the action of kinases in phase-separated condensates, however, are unknown. Knowledge of these mechanisms is crucial for the development of better drugs that target protein kinases. To address this challenge, I have designed an interdisciplinary project that goes well beyond the state-of-the-art to explore in atomic detail the action of protein kinases intimately involved in Alzheimers disease and the abnormal phosphorylation of the protein Tau.

The PhaseKin project aims to (i) reveal the specificity and reaction kinetics of protein kinases inside phase-separated condensates in vitro and in cells, (ii) decipher the dynamic conformational landscape of the protein kinases MARK2 and GSK3 by advanced NMR methods that will grant unprecedented detail on their modes of regulation, (iii) disentangle changes in population distributions and rates of interconversion between structurally distinct kinase states inside condensates, (iv) unravel the physicochemical basis of kinase drug partitioning into condensates.

The highly innovative nature of the project is devised to delve into the heart of protein kinase function and to revolutionize our knowledge about the chemistry of drug-kinase interactions. Findings from the PhaseKin project will provide critical guidance in the development of more efficacious and specific drugs which target protein kinases.

Topics

Who is involved

OrganisationCityCountryRole
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI